House Publications
The Debates are the report—transcribed, edited, and corrected—of what is said in the House. The Journals are the official record of the decisions and other transactions of the House. The Order Paper and Notice Paper contains the listing of all items that may be brought forward on a particular sitting day, and notices for upcoming items.
For an advanced search, use Publication Search tool.
If you have any questions or comments regarding the accessibility of this publication, please contact us at accessible@parl.gc.ca.
|
|
|
Notice PaperNo. 16 Tuesday, September 20, 2011 10:00 a.m. |
|
|
|
|
Introduction of Government Bills |
|
| September 19, 2011 — The Minister of Labour — Bill entitled “An Act to provide for the resumption and protection of air service operations”. |
| Recommendation |
| (Pursuant to Standing Order 79(2)) |
| Her Excellency the Governor General recommends to the House of Commons the appropriation of public revenue under the circumstances, in the manner and for the purposes set out in a measure entitled “An Act to provide for the resumption and protection of air service operations”. |
Introduction of Private Members' Bills |
|
| September 19, 2011 — Mr. Garrison (Esquimalt—Juan de Fuca) — Bill entitled “An Act to amend the Canadian Human Rights Act and the Criminal Code (gender identity and gender expression)”. |
|
|
| September 19, 2011 — Mr. Tweed (Brandon—Souris) — Bill entitled “An Act to amend the Canada Post Corporation Act (library materials)”. |
|
|
| September 19, 2011 — Ms. Duncan (Etobicoke North) — Bill entitled “An Act to establish a National Strategy for Chronic Cerebrospinal Venous Insufficiency (CCSVI)”. |
|
|
| September 19, 2011 — Mr. Goodale (Wascana) — Bill entitled “An Act to amend the Canada Transportation Act (discontinuance of listed sidings)”. |
Notices of Motions (Routine Proceedings) |
|
| September 19, 2011 — Mr. Angus (Timmins—James Bay) — That the report of the Office of the Conflict of Interest and Ethics Commissioner in relation to the former Member for Simcoe—Grey, presented by the Speaker on Monday, September 19, 2011, be referred to the Standing Committee on Procedure and House Affairs and that the Committee study the report with a view to further investigate the Commissioner’s findings in order to resolve outstanding questions; and that the Committee report their findings to the House no later than six months after the adoption of this motion. |
Questions |
|
| Q-1402 — September 19, 2011 — Ms. Duncan (Etobicoke North) — With respect to development of the oil sands, its impacts on the environment and surrounding communities, and the economic effects of these impacts: (a) what, if any, steps has the government taken to establish air emission limits or air quality standards to achieve the World Health Organization’s Air Quality Guidelines to protect air quality and human health; (b) what, if any, steps has the government’s sector-by-sector approach taken to regulate carbon emissions in the oil sands to ensure the oil sands industry makes appropriate reductions in its greenhouse gas (GHG) emissions to contribute to Canada’s GHG emission reduction goal of 17% below the 2005 level; (c) what, if any, studies has the government undertaken to examine the effect of the oil sands expansion on (i) GHG emissions, (ii) Canada’s ability to meet its GHG emission reduction goals, (iii) Canada’s contribution to the goal of staying below a 2°C increase in global average surface temperature, relative to the pre-industrial level, as articulated at the G8 meeting in L’Aquila, Italy and at the United Nations Framework Convention on Climate Change negotiations through the Copenhagen Accord in December 2009 and the Cancun Agreements in December 2010, (iv) the full suite of sustainability criteria, including environmental, economic and social sustainability, and (v) what were the results of any studies identified in (c)(i), (c)(ii), (c)(iii), and (c)(iv); (d) what, if any, studies has the government undertaken to examine (i) the scope of oil sands expansion if the oil sands sector is not required to deliver its proportional share of GHG reductions, (ii) the impacts such a decision would have on other sectors’ allowable GHG emissions, (iii) whether other sectors of the Canadian economy would have to do more than their proportional share to reduce emissions, (iv) what were the results of any studies identified in (d)(i), (d)(ii), and (d)(iii); (e) what, if any, studies has the government undertaken to assess safety, risks and effectiveness of carbon capture and storage (CCS) and what were the results of any identified study; (f) what, if any, studies, has the government undertaken to assess safety, risks and effectiveness of enhanced oil recovery and what were the results of any identified study; (g) what, if any, studies has the government undertaken to examine the possible impact of CCS technology on GHG emissions in the oil sands, (i) what are the government’s projections for the level of reductions that is feasible with CCS, (ii) what are the government’s projections for how CCS technology would impact oil sands emissions by 2020 and by 2050, (iii) does the government project that an oil sands industry equipped with CCS technology would be able to meet the specific reductions targets established by the government for 2020 and 2050; (h) how does the government plan to address emissions that cannot be reduced by CCS, such as (i) emissions from smaller in situ projects, (ii) mine fleet emissions, (iii) tailings fugitives; (i) what, if any, steps has the government taken to set an economy-wide price on carbon, rather than a sector-by-sector regulatory approach, as a means to reducing GHG emissions from the oil sands; (j) what, if any, steps has the government taken to adopt regulations to require all new oil sands facilities that began operations in 2010 or later to implement full-scale CCS by 2015, and will projects for which CCS is not an option still be approved by the government, whenever such approval is required for the project to proceed; (k) what, if any, steps has the government taken to quantify and eliminate air and water pollution discharge from tailings ponds by 2020 through Section 36(3) of the Fisheries Act (i) by identifying substances associated with tailings ponds as toxic under the Canadian Environmental Protection Act (CEPA), and (ii) what would be the projected impacts on the environment, human health, industry, and migratory birds of such legislative measures; (l) what, if any steps has the government taken to implement its phase ll monitoring plan (i) when will data collection of begin, (ii) when will data be available for inclusion in decision-making processes, (iii) will monitoring programs be reformed in advance of any new oil sands expansion; (m) what steps is the government taking to ensure sufficient capacity exists to (i) implement the Northwest Territories Water Strategy, (ii) help reform water monitoring in the Mackenzie River Basin; (n) what, if any, steps has the government taken to develop a federal emergency response plan to strengthen the Mackenzie River Basin Transboundary Waters Master Agreement in case of a failure of a tailings lake dyke; (o) are Mackenzie River Basin residents in particular and Canadians in general financially protected from a major industrial accident such as the failure of a tailings dyke and, (i) if so, why are both groups protected, (ii) if not, why, and does the government plan to implement measures to ensure these groups are protected; (p) what, if any, studies has the government undertaken to identify critical habitats for woodland caribou in north-eastern Alberta, and what were the conclusions of each study, including the results of consultations with First Nations on conservation of woodland caribou; (q) what, if any, studies has the government undertaken to determine the level of oil sands development that is consistent with caribou conservation in Alberta; and (r) does the government plan (i) to conduct a comprehensive health study of the impacts of oil sands development on surrounding communities, (ii) to identify and implement measures to reduce any health impacts discovered in such a study? |
| Q-1412 — September 19, 2011 — Ms. Duncan (Etobicoke North) — With respect to climate change and international and national security: (a) what does the government project are the potential impacts on currently stable regions of the world of such climate change-related phenomena as, but not limited to, (i) rises in sea level, (ii) increases in extreme weather events, (iii) increases in the spread of infectious disease, (iv) increases in environmental refugees; (b) what does the government project will be (i) the consequences of the impacts identified in (a)(ii), (a)(iii), and (a)(iv) on domestic military missions, (ii) the consequences of (a)(i), (a)(ii), (a)(iii), (a)(iv) and (b)(i) in terms of the military’s capacity to respond and the availability of troops for missions not related to conflicts induced by climate change-related phenomena; (c) what does the government project will be the potential impacts on already-weakened states of such climate change-related phenomena as, but not limited to, (i) sea level rise, (ii) extreme weather events, (iii) the spread of infectious diseases; (d) what does the government project will be the extent of the effects climate impacts could have on already-weakened states, including, but not limited to, (i) expanded ungoverned spaces, (ii) further weakened and failed states, (iii) increased conflicts, (iv) increased migrations; (e) what does the government project will be the impact of the effects identified in (d) on Canada’s national security; (f) which nations does the government project will be most affected by climate change, (i) what is the government’s assessment of each such country’s capacity to adapt or cope, (ii) what, if any, action is Canada taking to strengthen the capacity of weak governments to better cope with societal needs projected to arise as a result of climate change-related impacts, (iii) what is the government’s assessment of possible security risks if Canada does contribute to international efforts related to (f)(i) and (f)(ii); (g) has DND or the Canadian military conducted any studies of how climate change can have a multiplier effect on instability in unstable regions of the world and, if so, what were these studies and their results; (h) what are the studies, along with their dates and results, undertaken by the government concerning the possible national security risks of climate change, and what specific observations were included in these studies concerning the impacts the research might have for government efforts pertaining to, but not limited to, (i) the encouragement of regional cooperation, (ii) the improvement of international confidence, (iii) the improvement of public relations; (i) what, if any, departments have participated in an inter-departmental process to develop a policy to reduce national security risks resulting from climate change and (i) if departments have participated in such a process, have all agencies involved with climate science, treaty negotiations, economic policy, and national security been involved in the process, and what were the results, (ii) if departments have not participated in such a process, why not; (j) what, if any, strategies has the government developed, including the dates of each completed strategy, concerning the integration of the national security consequences of climate change into national security and national defence strategies, and if the government has developed such strategies, (i) do the strategies examine the capabilities of the Canadian military to respond to the consequences of climate change, (ii) do the strategies include guidance to military planners to assess climate change risks on future missions, (iii) do the strategies provide guidance for updating defence plans based on new assessments; (k) for each strategy identified in (j), what are (i) the details of any testing of the strategy that has been conducted, (ii) the details of the implementation of the strategy, including, but not limited to, working with allies and partners to incorporate climate mitigation strategies, capacity building, and relevant research and development; (l) what are the government’s plans as concerns its engagement in global partnerships intended to help less developed nations build the capacity and resiliency to better manage climate impacts; and (m) what, if any, conferences has DND undertaken with respect to climate change and national security, if no such conferences have been undertaken, why not, and, if any such conferences have been undertaken, (i) who participated, (ii) what topics were covered, (iii) what findings were made, (iv) what recommendations were made, (v) what follow-up has occurred? |
| Q-1422 — September 19, 2011 — Ms. Duncan (Etobicoke North) — With respect to the venous system, and more particularly, chronic cerebrospinal venous insufficiency (CCSVI): (a) what, if any, steps is the government taking to address research questions regarding the venous system, including (i) what does the normal venous system look like, and, specifically, what does it look like in infants, children, and adults, (ii) can the veins, in particular the jugulars and the azygous, look normal, and the flow be abnormal, (iii) what is the normal range of flow through veins, in particular the jugulars and the azygous, (iv) how should normal range of flow through veins, in particular the jugulars and azygous, be defined, (v) what is the normal range of blood gases in veins, in particular the jugulars and the azygous, (vi) what causes venous pathology and when does it occur, (vii) theoretically, what is the complete range of possible vascular problems in the head, neck, chest, and spine, which ones might impact health, and specifically which ones might be linked to multiple sclerosis (MS), (viii) how does the complete range of possible vascular problems compare with those actually seen in patients, (ix) how should abnormal flow through veins, in particular the jugulars and the azygous, be defined, (x) how might abnormal blood gases in veins affect health in the short-term and long-term, (xi) what, if any, reflux is normal in veins, and, if some reflux is normal, what is the ‘tipping point’ to abnormal, (xii) can a catalogue of venous pathology (in the head, neck, chest and spine), abnormal flow, and potential health impacts be established, (xiii) what protects against abnormal venous pathology and abnormal flow, (xiv) who should receive venous protective measures, and when should protective measures be put in place; (b) what, if any, steps is the government taking to address research questions regarding the venous system and MS, including, (i) can fluid mechanics predict where physiologic changes in the brain might occur, (ii) how does the neurologist’s understanding of flow through the brain compare with that of physicists, (iii) does decreased metabolism lead to hypoxia which may lead to endothelial damage and inflammation, (iv) what occurs first, inflammatory changes in the brain or iron deposition, (v) what role does reduced perfusion have in MS, (vi) does stenosis extra-cranially cause less perfusion in the brain, (vii) does stenosis extra-cranially cause morphological changes in the brain, (viii) do cerebral veins actually disappear over time, or is it merely a lack of flow that makes them look like they disappear in magnetic resonance imaging (MRI) studies; (ix) what, if any changes beyond lesions, occur in the spinal cord of MS patients, as a result of reduced vertebral flow, (x) do vertebral veins show a similar disappearance over time, (xi) what percentage of MS patients show evidence of venous pathology, as compared to 'normals', (xii) what other venous abnormalities might MS patients have (e.g., bladder, intestine, kidney), might these abnormalities play a role in their disease, and, if so, how should they be imaged and treated, (xiii) what percentage of MS patients show venous abnormalities below the chest (e.g., May Thurner syndrome), and does this have an impact on their disease, (xiv) how does the vascular system of someone with benign MS compare to that of someone with relapsing-remitting, primary progressive or secondary progressive MS; (c) what, if any, steps is the government taking to address research questions regarding CCSVI and MS, including, (i) what is the prevalence of CCSVI in relapsing-remitting, primary progressive or secondary progressive MS, (ii) does CCSVI worsen over time with the progression of disease, (iii) does CCSVI play a role in MS, and, if so, how, (iv) is CCSVI specific to MS, (v) what are the potential health impacts of CCSVI in the short-term, medium-term and long-term, both with and without treatment; (d) what, if any, steps is the government taking to address research questions regarding CCSVI diagnosis, including (i) how do the results of MRI compare with those of ultrasound for diagnosis of CCSVI, (ii) what is the best way to image the venous system and the best way to image venous pathology, (iii) what are the limitations of current diagnostic tools to image the venous system, (iv) should intravascular ultrasound be used, and what are the benefits and the risks, (v) what is the learning curve for the various diagnostic procedures, and what should practitioners undertake to become sufficiently accomplished, (vi) can a standardized protocol be established for diagnosing CCSVI in MS patients, and when should MS patients be tested for CCSVI, (vii) can a standardized system for describing lesions (e.g., type, location) be established, (viii) what should be the decision-making process regarding whether to treat or not to treat (e.g., anatomy, flow, etc.), (ix) should arterial, venous and CSF flow be monitored, how often, and for what purpose, (x) should lesions and iron load be monitored, how often, and for what purpose; (e) what, if any, steps is the government taking to address research questions regarding CCSVI treatment, including (i) what timescale is useful for treatment of CCSVI, (ii) what are the benefits and risks associated with treatment of CCSVI, (iii) what are best practices for treating each identified vascular problem, (iv) how should a successful CCSVI treatment be defined (e.g., valvular correction, reduction in stenosis, increased flow, improved blood gases), (v) can malformed jugulars and azygous be treated to achieve normal flow, (vi) can malformed jugulars and azygous be treated to achieve a normal range of blood gases, (vii) can jugulars and azygous be sufficiently treated to make up for poor vertebral flow, and, if not, what procedures can be developed to improve vertebral flow, (viii) should stents be used, and, if so, under what circumstances, (ix) what are the immediate complications of CCSVI treatment, and in what percentage of treatments does each occur for each identified abnormality, (x) what is the best follow-up anti-coagulant therapy, what are the potential risks, and what is the prevalence of complications, (xi) what are the best follow-up therapies, including, brain plasticity exercises, nutrition, physiotherapy, speech therapy, etc., and which therapies have the best associated outcomes, (xii) what are late complications, what follow-up is necessary to determine late complications, and in what percentage of treatments does each occur for each identified abnormality, (xiii) what treatments are available should a stent be occluded, either through hyperplasia or thrombosis, (xiv) what is the success rate of each identified treatment for an occluded stent; (f) what, if any, steps is the government taking to address research questions regarding determining the best CCSVI treatment, including, (i) is CCSVI treatment with the addition of pharmacological agents more efficacious than just the CCSVI procedure, (ii) what pharmacological agents could be used to treat venous inflammation, iron storage, and hydrocephaly, and could these agents be added to CCSVI treatment, (iii) what safe apparatuses could be developed to keep treated veins open, (iv) are vein grafts possible, and if so, on whom, and when should they be used, (v) is CCSVI treatment more efficacious with mesenchymal-derived or adipose-derived stem-cell infusion than just the CCSVI procedure alone, (vi) what methods might be added to reduce permeability of the blood-brain barrier, including pharmacological agents and stem cells, (vii) what are the effects of chelators on iron uptake and release from the brain, and might iron chelators be used as therapeutic agents; (g) what, if any, steps is the government taking to address research questions regarding possible impacts of CCSVI treatment on MS patients, including (i) what impact does CCSVI treatment have on patients immediately, (ii) what impact does CCSVI treatment have on patients at 24 hours, 3 months, 6 months, 1 year, and 2 years, (iii) what does the magnetic resonance venography (MRV) of a treated patient look like at 24 hours, 3 months, 6 months, 1 year, and 2 years, (iv) what percentage of MS patients show functional improvement at 3 months, 6 months, 1 year, and 2 years, (v) what are the most appropriate scales to measure any health impacts following CCSVI treatment as reported by MS patients, (vi) do new scales have to be created to measure reported changes following treatment, (vii) which patients show the greatest improvement, and does early intervention allow for a better outcome, (viii) what are the treatment outcomes associated with each of the identified venous problems, (ix) what percentage of MS patients show a reduction in MS attacks and brain lesions following the CCSVI procedure, (x) what percentage of MS patients with little or mild blockage show improvement following the CCSVI procedure, (xi) for those MS patients whose conditions do not improve or become worse, why does this occur; (h) what, if any, steps is the government taking to address research questions regarding CCSVI re-stenosis and diagnosis, including, (i) what is rate of stenosis for each identified vascular abnormality, (ii) what changes should patients be told to look for to in order to recognize whether they are possibly re-stenosing, (iii) what diagnostic methods should be used after treatment for CCSVI, (iv) what diagnostic methods should be used to look for re-stenosis, and at what timescales; (i) what, if any, steps is the government taking to address research questions regarding secondary procedures for CCSVI, including, (i) are secondary procedures safe, and if so, how many, (ii) what should be the follow-up protocol for secondary procedures, (iii) should there be a methodology established regarding whether to do a secondary procedure or not; and (j) what, if any, steps is the government taking to address research questions regarding prevention in the next generation, including, (i) do vascular issues develop in utero, during childhood, or later, and what would be the best methods to discover circulation problems at the earliest time possible to avoid health impacts at a later date, (ii) might vascular birthmarks and tumours be an indication of potential vascular problems, (iii) might skin discolouration, skin abnormalities, and even proliferation of moles be an indication of an autoimmune or neural condition, (iv) might giving vitamin D to pregnant mothers reduce the risk of children being born with, or developing, vascular problems and other conditions and, if so, what dosage is appropriate, (v) do antioxidants, vitamin D and omega 3 reduce vein inflammation, (vi) will giving children and adolescents vitamin D reduce the risk of developing vein inflammation and venous hypertension and, if so, what dosage is appropriate, and what quantity should be recommended for a child with a family history of CCSVI, vascular problems or MS, etc., (vii) what would be the optimum time to undertake CCSVI treatment to avoid health impacts at a later date? |
| Q-1432 — September 19, 2011 — Mr. Simms (Bonavista—Gander—Grand Falls—Windsor) — With regard to the Service Canada Employment Insurance (EI) Modernization plan: (a) what are the itemized costs incurred for operating the EI Processing Unit in Gander, Newfoundland and Labrador (NL); (b) what are the itemized costs incurred for operating the EI Processing Unit in St. John’s, NL; (c) what are the itemized costs for transferring the EI Processing Unit from Gander to St. John’s including, but not limited to, severance pay, relocation allowances, building costs for the new facility (Pippy Place); (d) what are the itemized costs for transferring the EI Processing Unit from Grand Falls-Windsor to St. John’s; (e) how many employees are working in each EI Processing Unit in NL, including the units in (i) Gander, (ii) Grand Falls-Windsor, (iii) St. John’s; (f) what are the itemized cost savings realized by consolidating all NL EI Processing sites in St. John’s; (g) what criteria were used in deciding that St. John’s is the most appropriate and cost-effective location for an EI Processing Centre in NL, as opposed to Gander; and (h) what is the estimated time frame for the closing of the EI Processing Units in Gander and Grand Falls-Windsor? |
| Q-1442 — September 19, 2011 — Mr. Toone (Gaspésie—Îles-de-la-Madeleine) — With regard to Service Canada programs and services within the riding of Gaspésie—Îles-de-la-Madeleine: (a) what is the current baseline for service; (b) what value-for-money studies, reviews or summaries have been undertaken relating to Service Canada programs; (c) what are the recommended changes in Service Canada programs in Gaspésie—Îles-de-la-Madeleine; (d) what is the level of spending on Service Canada operations in the riding for this year and 2010–2011; (e) what is the planned level of spending on Service Canada operations in the riding for 2012–2013 and 2013–2014; (f) what are the numbers for Full Time Equivalents (FTEs) for this year and 2010–2011 in the riding; (g) what are the planned numbers of FTEs for 2012–2013 and 2013–2014 in the riding; (h) how many clients did Service Canada serve in the riding this year and 2010–2011; (i) what is the number of inquiries per FTE for this year and 2010–2011; and (j) what is the demographic make-up of the clients served in the riding this year and in 2010–2011? |
Notices of Motions for the Production of Papers |
|
Business of Supply |
|
Government Business |
|
| No. 4 — September 19, 2011 — The Leader of the Government in the House of Commons — That, notwithstanding any Standing Order or usual practice of the House, a bill in the name of the Minister of Labour, entitled An Act to provide for the resumption and protection of air service operations, shall be disposed of as follows: |
| (a) the said bill may be read twice or thrice in one sitting; |
| (b) not more than two hours shall be allotted for the consideration of the second reading stage of the said bill, following the adoption of this Order; |
| (c) when the bill has been read a second time, it shall be referred to a Committee of the Whole; |
| (d) not more than one hour shall be allotted for the consideration of the Committee of the Whole stage of the said bill; |
| (e) not more than one-half hour shall be allotted for the consideration of the third reading stage of the said bill, provided that no Member shall speak for more than ten minutes at a time during the said stage and that no period for questions and comments be permitted following each Member’s speech; |
| (f) at the expiry of the times provided for in this Order, any proceedings before the House or the Committee of the Whole shall be interrupted, if required for the purpose of this Order, and, in turn, every question necessary for the disposal of the stage, then under consideration, of the said bill shall be put and disposed of forthwith and successively, without further debate or amendment, and no division shall be deferred; |
| (g) no motion to adjourn the House may be proposed except by a Minister of the Crown; |
| (h) no motion to adjourn the debate at any stage of the said bill may be proposed except by a Minister of the Crown; and |
| (i) during the consideration of the said bill in the Committee of the Whole, no motions that the Committee rise or that the Committee report progress may be proposed except by a Minister of the Crown. |
Private Members' Notices of Motions |
|
Private Members' Business |
|
|
|
| 2 Response requested within 45 days |
|